SPTLC1 Protein (Serine Palmitoyltransferase 1)

Overview

SPTLC1 Protein (Serine Palmitoyltransferase 1)
Protein Name	Serine Palmitoyltransferase Long Chain Base Subunit 1
Gene Symbol	SPTLC1
Alternative Names	SPT1, LCB1, SPT-1
Subunit Type	Catalytic subunit
Chromosomal Location	9q22.31
NCBI Gene ID	10578
UniProt ID	O15269
Protein Length	473 amino acids
Molecular Weight	~53 kDa
Expression	Ubiquitous, highest in brain, liver, kidney
Tissue	Expression Level
Brain	High
Liver	High
Kidney	High
Heart	Moderate
Lung	Moderate
Pancreas	Moderate
Skeletal muscle	Low
Adipose tissue	Moderate
Protein/Entity	Interaction Type
SPTLC2	Subunit assembly
SPTLC3	Subunit assembly
SPTLC4	Interaction
ORMDL proteins	Regulation
CERT	Lipid transport
Pitman network	Regulation
HMG-CoA reductase	Pathway
CERT	Interaction
Associated Diseases	Als, Amyotrophic Lateral Sclerosis, Amyotrophic lateral sclerosis, Juvenile amyotrophic lateral sclerosis, Neuropathy
SciDEX Hypotheses	APOE-Mediated Synaptic Lipid Raft Stabil...
KG Connections	25 edges

The SPTLC1 gene (Serine Palmitoyltransferase Long Chain Base Subunit 1) encodes the SPTLC1 protein, the catalytic subunit of serine palmitoyltransferase (SPT), the rate-limiting enzyme in de novo sphingolipid biosynthesis. SPT catalyzes the condensation of L-serine with palmitoyl-CoA to form 3-ketosphinganine, the first and committed step in sphingolipid synthesis. SPTLC1 is essential for cellular membrane integrity, lipid raft formation, and signaling transduction. Mutations in SPTLC1 cause hereditary sensory and autonomic neuropathy type 1 (HSAN1), a devastating peripheral neuropathy characterized by sensory loss, ulcerations, and sometimes motor involvement. Additionally, SPTLC1 dysfunction has been implicated in Alzheimer’s disease, Parkinson’s disease, and metabolic disorders.

Introduction

Sphingolipids are essential structural components of eukaryotic cell membranes and serve as critical signaling molecules involved in cell growth, differentiation, apoptosis, and stress responses^{1Hanada K. (2003). Serine palmitoyltransferase, a key enzyme of de novo sphingolipid biosynthesis. Biol Pharm Bull 26(6):759-7652003 · PMID 12808286Open reference}. Serine palmitoyltransferase (SPT) catalyzes the first committed step in sphingolipid biosynthesis, making it a key regulatory point for cellular sphingolipid homeostasis^{2Merrill AH Jr. (2011). Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem Rev 111(10):6387-64222011 · PMID 21939287Open reference}. The SPT enzyme is a heterodimer composed of SPTLC1 (catalytic subunit) and SPTLC2 (or SPTLC3), which together form the functional holoenzyme^{3(2006). The mammalian serine palmitoyltransferase complex. Cell Mol Life Sci 63(12):1330-13412006 · PMID 16729022Open reference}. SPTLC1 is ubiquitously expressed with highest levels in the brain, liver, and kidney, reflecting the high sphingolipid demand in these tissues^{4(2020). SPTLC1 expression in human tissues. J Lipid Res 61(10):1420-14322020 · DOI 10.1194/jlr.RA120000678Open reference}.

This comprehensive analysis covers SPTLC1 structure, enzymatic function, disease associations, therapeutic implications, and current research directions.

Protein Structure and Basic Information

Enzyme Function

Catalytic Mechanism

Serine palmitoyltransferase (SPT) catalyzes the pyridoxal 5’-phosphate (PLP)-dependent condensation reaction^{1Hanada K. (2003). Serine palmitoyltransferase, a key enzyme of de novo sphingolipid biosynthesis. Biol Pharm Bull 26(6):759-7652003 · PMID 12808286Open reference2Merrill AH Jr. (2011). Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem Rev 111(10):6387-64222011 · PMID 21939287Open reference}:

1. Substrate binding: L-serine and palmitoyl-CoA bind to the active site

2. Condensation: PLP forms a Schiff base with L-serine, facilitating nucleophilic attack on palmitoyl-CoA

3. Product release: 3-ketosphinganine is released and subsequently reduced to sphinganine

4. CoA release: CoA is released, completing the catalytic cycle

Subunit Composition

The functional SPT enzyme exists as multiple isoforms^{3(2006). The mammalian serine palmitoyltransferase complex. Cell Mol Life Sci 63(12):1330-13412006 · PMID 16729022Open reference5(2009). Structure and function of human serine palmitoyltransferase. Cell Mol Life Sci 66(20):3241-32612009 · PMID 19657166Open reference}:

• SPTLC1 + SPTLC2: Predominant isoform in most tissues

• SPTLC1 + SPTLC3: Minor isoform with distinct substrate specificity

• SPTLC1 + SPTLC2 + SPTLC3: Heterotrimeric complexes in some tissues

Substrate Specificity

SPT exhibits broad substrate specificity^{2Merrill AH Jr. (2011). Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem Rev 111(10):6387-64222011 · PMID 21939287Open reference5(2009). Structure and function of human serine palmitoyltransferase. Cell Mol Life Sci 66(20):3241-32612009 · PMID 19657166Open reference}:

• CoA thioesters: Palmitoyl-CoA, stearoyl-CoA, myristoyl-CoA

• Amino acids: L-serine (primary), L-alanine (minor)

• Alternative substrates: Various synthetic analogs

Physiological Roles

SPTLC1 and SPT play essential roles in cellular physiology^{2Merrill AH Jr. (2011). Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem Rev 111(10):6387-64222011 · PMID 21939287Open reference}0^{2Merrill AH Jr. (2011). Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem Rev 111(10):6387-64222011 · PMID 21939287Open reference}1^{2Merrill AH Jr. (2011). Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem Rev 111(10):6387-64222011 · PMID 21939287Open reference}2:

1. Sphingolipid synthesis: Rate-limiting step in de novo sphingolipid biosynthesis

2. Membrane integrity: Provides ceramides for complex sphingolipids

3. Lipid raft formation: Generates raft-forming sphingolipids

4. Cell signaling: Produces bioactive sphingolipids (ceramides, S1P)

5. ER stress response: Involved in unfolded protein response

6. Apoptosis regulation: Ceramide-mediated cell death pathways

7. Immune function: Sphingolipid mediators in inflammation

Sphingolipid Metabolism Pathway

The sphingolipid biosynthetic pathway branches from SPT activity^{2Merrill AH Jr. (2011). Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem Rev 111(10):6387-64222011 · PMID 21939287Open reference}3^{2Merrill AH Jr. (2011). Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem Rev 111(10):6387-64222011 · PMID 21939287Open reference}4:

L-serine + Palmitoyl-CoA → 3-ketosphinganine → Sphinganine
                                                    ↓
                                          Sphingosine → Ceramide
                                                    ↓
                              Complex sphingolipids (GSLs, SM)
                                                    ↓
                                          Bioactive metabolites (S1P, C1P)

Expression Pattern

SPTLC1 shows tissue-specific expression patterns^{2Merrill AH Jr. (2011). Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem Rev 111(10):6387-64222011 · PMID 21939287Open reference}5^{2Merrill AH Jr. (2011). Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem Rev 111(10):6387-64222011 · PMID 21939287Open reference}6:

Cellular Localization

SPTLC1 is localized to the endoplasmic reticulum (ER)^{2Merrill AH Jr. (2011). Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem Rev 111(10):6387-64222011 · PMID 21939287Open reference}7^{2Merrill AH Jr. (2011). Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem Rev 111(10):6387-64222011 · PMID 21939287Open reference}8:

• ER membrane: Integral membrane protein

• Active site: Lumenal orientation

• Substrate access: Cytosolic CoA thioesters

Disease Associations

Hereditary Sensory and Autonomic Neuropathy Type 1 (HSAN1)

Mutations in SPTLC1 cause HSAN1, an autosomal dominant peripheral neuropathy^{2Merrill AH Jr. (2011). Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem Rev 111(10):6387-64222011 · PMID 21939287Open reference}9^{3(2006). The mammalian serine palmitoyltransferase complex. Cell Mol Life Sci 63(12):1330-13412006 · PMID 16729022Open reference}0^{3(2006). The mammalian serine palmitoyltransferase complex. Cell Mol Life Sci 63(12):1330-13412006 · PMID 16729022Open reference}1^{3(2006). The mammalian serine palmitoyltransferase complex. Cell Mol Life Sci 63(12):1330-13412006 · PMID 16729022Open reference}2:

• C133W and C133Y mutations: Most common pathogenic variants

• D136G, V144M, L239F: Additional pathogenic variants identified

• Pathogenic mechanism: Gain-of-function causing increased S1P production

• Onset: Usually in second or third decade

• Clinical features:

  • Progressive sensory loss (starting in feet)

  • Ulcerations and mutilating deformities

  • Variable motor involvement

  • Reduced pain and temperature sensation

  • Intact motor function initially

• Inheritance: Autosomal dominant with variable expressivity

• Prevalence: ~1:500,000 to 1:1,000,000

Alzheimer’s Disease

SPTLC1 dysfunction contributes to Alzheimer’s disease pathogenesis^{3(2006). The mammalian serine palmitoyltransferase complex. Cell Mol Life Sci 63(12):1330-13412006 · PMID 16729022Open reference}3^{3(2006). The mammalian serine palmitoyltransferase complex. Cell Mol Life Sci 63(12):1330-13412006 · PMID 16729022Open reference}4^{3(2006). The mammalian serine palmitoyltransferase complex. Cell Mol Life Sci 63(12):1330-13412006 · PMID 16729022Open reference}5:

• Altered sphingolipid metabolism in AD brain

• Role in amyloid-beta toxicity

• Ceramide accumulation in neurons

• Sphingolipid raft disruption

• Potential therapeutic target

Parkinson’s Disease

SPTLC1 is implicated in PD through^{3(2006). The mammalian serine palmitoyltransferase complex. Cell Mol Life Sci 63(12):1330-13412006 · PMID 16729022Open reference}6^{3(2006). The mammalian serine palmitoyltransferase complex. Cell Mol Life Sci 63(12):1330-13412006 · PMID 16729022Open reference}7^{3(2006). The mammalian serine palmitoyltransferase complex. Cell Mol Life Sci 63(12):1330-13412006 · PMID 16729022Open reference}8:

• Dysregulated sphingolipid metabolism in PD brain

• Role in alpha-synuclein aggregation

• Mitochondrial dysfunction

• Ceramide-mediated apoptosis

• Potential biomarker

Amyotrophic Lateral Sclerosis (ALS)

Emerging evidence links SPTLC1 to ALS^{3(2006). The mammalian serine palmitoyltransferase complex. Cell Mol Life Sci 63(12):1330-13412006 · PMID 16729022Open reference}9:

• Altered sphingolipid metabolism in ALS motor neurons

• Role in ER stress

• Potential therapeutic target

• Biomarker potential

Metabolic Disorders

SPTLC1 variants associated with^{4(2020). SPTLC1 expression in human tissues. J Lipid Res 61(10):1420-14322020 · DOI 10.1194/jlr.RA120000678Open reference}0^{4(2020). SPTLC1 expression in human tissues. J Lipid Res 61(10):1420-14322020 · DOI 10.1194/jlr.RA120000678Open reference}1:

• Type 2 diabetes

• Metabolic syndrome

• Fatty liver disease

• Insulin resistance

Pathogenic Mechanisms

HSAN1 Pathogenesis

Mutant SPTLC1 causes disease through gain-of-function^{4(2020). SPTLC1 expression in human tissues. J Lipid Res 61(10):1420-14322020 · DOI 10.1194/jlr.RA120000678Open reference}2^{4(2020). SPTLC1 expression in human tissues. J Lipid Res 61(10):1420-14322020 · DOI 10.1194/jlr.RA120000678Open reference}3^{4(2020). SPTLC1 expression in human tissues. J Lipid Res 61(10):1420-14322020 · DOI 10.1194/jlr.RA120000678Open reference}4:

1. Altered substrate specificity: Mutations change SPT substrate usage

2. Increased deoxysphingolipid production: Toxic 1-deoxysphinganine accumulation

3. ER stress activation: Unfolded protein response

4. Mitochondrial dysfunction: Energy metabolism impairment

5. Neuronal death: Sensory neuron degeneration

Neurodegeneration Mechanisms

In Alzheimer’s and Parkinson’s disease^{4(2020). SPTLC1 expression in human tissues. J Lipid Res 61(10):1420-14322020 · DOI 10.1194/jlr.RA120000678Open reference}5^{4(2020). SPTLC1 expression in human tissues. J Lipid Res 61(10):1420-14322020 · DOI 10.1194/jlr.RA120000678Open reference}6^{4(2020). SPTLC1 expression in human tissues. J Lipid Res 61(10):1420-14322020 · DOI 10.1194/jlr.RA120000678Open reference}7:

1. Ceramide accumulation: Pro-apoptotic signaling

2. Lipid raft disruption: Altered signaling platform function

3. ER stress: Unfolded protein response activation

4. Mitochondrial dysfunction: Energy production deficits

5. Autophagy impairment: Protein clearance defects

Therapeutic Implications

HSAN1 Treatment

Current therapeutic approaches for HSAN1^{4(2020). SPTLC1 expression in human tissues. J Lipid Res 61(10):1420-14322020 · DOI 10.1194/jlr.RA120000678Open reference}8^{4(2020). SPTLC1 expression in human tissues. J Lipid Res 61(10):1420-14322020 · DOI 10.1194/jlr.RA120000678Open reference}9^{1Hanada K. (2003). Serine palmitoyltransferase, a key enzyme of de novo sphingolipid biosynthesis. Biol Pharm Bull 26(6):759-7652003 · PMID 12808286Open reference}0:

• Myriocin: SPT inhibitor, in clinical trials

• Fingolimod (FTY720): S1P receptor modulator

• Gene therapy: Targeting mutant allele

• Symptomatic management: Wound care, pain management

• Physical therapy: Prevent injury

Neurodegenerative Disease

SPTLC1 modulation represents a therapeutic strategy for AD/PD/ALS^{1Hanada K. (2003). Serine palmitoyltransferase, a key enzyme of de novo sphingolipid biosynthesis. Biol Pharm Bull 26(6):759-7652003 · PMID 12808286Open reference}1^{1Hanada K. (2003). Serine palmitoyltransferase, a key enzyme of de novo sphingolipid biosynthesis. Biol Pharm Bull 26(6):759-7652003 · PMID 12808286Open reference}2^{1Hanada K. (2003). Serine palmitoyltransferase, a key enzyme of de novo sphingolipid biosynthesis. Biol Pharm Bull 26(6):759-7652003 · PMID 12808286Open reference}3:

• SPT inhibitors: Reduce toxic sphingolipid accumulation

• Ceramide modulators: Restore lipid homeostasis

• S1P receptor modulators: Modify signaling

• Targeted delivery: Brain-penetrant small molecules

Challenges

Therapeutic development faces challenges:

• Systemic toxicity: SPT inhibition affects all tissues

• Specificity: Need tissue-selective targeting

• Delivery: Blood-brain barrier penetration required

• Therapeutic window: Balancing efficacy and toxicity

Key Interactions

Research Methods

Experimental Approaches

• Enzymology: SPT activity assays in vitro^{1Hanada K. (2003). Serine palmitoyltransferase, a key enzyme of de novo sphingolipid biosynthesis. Biol Pharm Bull 26(6):759-7652003 · PMID 12808286Open reference}4

• Genetics: GWAS, exome sequencing for variant identification^{1Hanada K. (2003). Serine palmitoyltransferase, a key enzyme of de novo sphingolipid biosynthesis. Biol Pharm Bull 26(6):759-7652003 · PMID 12808286Open reference}5^{1Hanada K. (2003). Serine palmitoyltransferase, a key enzyme of de novo sphingolipid biosynthesis. Biol Pharm Bull 26(6):759-7652003 · PMID 12808286Open reference}6

• Animal models: Transgenic and knockout mice^{1Hanada K. (2003). Serine palmitoyltransferase, a key enzyme of de novo sphingolipid biosynthesis. Biol Pharm Bull 26(6):759-7652003 · PMID 12808286Open reference}7

• Lipidomics: Mass spectrometry for sphingolipid profiling^{1Hanada K. (2003). Serine palmitoyltransferase, a key enzyme of de novo sphingolipid biosynthesis. Biol Pharm Bull 26(6):759-7652003 · PMID 12808286Open reference}8

• Cell biology: Subcellular localization, trafficking studies

Model Systems

• HEK293 cells: Heterologous expression studies

• Primary neurons: Neuronal function studies

• Patient-derived iPSCs: Disease modeling^{1Hanada K. (2003). Serine palmitoyltransferase, a key enzyme of de novo sphingolipid biosynthesis. Biol Pharm Bull 26(6):759-7652003 · PMID 12808286Open reference}9

• C. elegans: Genetic screening

• Mouse models: In vivo studies

Clinical Significance

Genetic Testing

SPTLC1 testing available for:

• HSAN1 diagnostic confirmation

• Carrier testing for at-risk families

• Prenatal diagnosis

• Differential diagnosis

Biomarkers

SPTLC1 activity may serve as:

• Disease progression marker in HSAN1

• Therapeutic response indicator

• Potential AD/PD/ALS biomarker

• Metabolic disease marker

Patient Management

Clinical care for HSAN1 patients^{2Merrill AH Jr. (2011). Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem Rev 111(10):6387-64222011 · PMID 21939287Open reference}0^{2Merrill AH Jr. (2011). Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem Rev 111(10):6387-64222011 · PMID 21939287Open reference}1:

• Regular neurological assessment

• Wound care and infection prevention

• Pain management strategies

• Physical therapy

• Genetic counseling

Animal Models

Mouse Models

• Sptlc1 conditional knockout: Tissue-specific deletion

• Sptlc1 transgenic: Overexpression studies

• HSAN1 knock-in: Disease modeling

Phenotypic Findings

Animal models reveal^{2Merrill AH Jr. (2011). Sphingolipid and glycosphingolipid metabolic pathways in the era of sphingolipidomics. Chem Rev 111(10):6387-64222011 · PMID 21939287Open reference}2:

• Peripheral neuropathy phenotype

• Altered sphingolipid levels

• Sensory neuron loss

• ER stress markers

Future Directions

Emerging Research Areas

• Gene editing: CRISPR-based therapies

• Small molecule inhibitors: Next-generation SPT modulators

• Biomarker development: Disease monitoring

• Patient stratification: Precision medicine approaches

See Also

• SPTLC1 Gene

• SPTLC2 Gene - SPT Catalytic Subunit 2

• SPTLC3 Gene - SPT Catalytic Subunit 3

• Hereditary Sensory Neuropathy

• Sphingolipid Metabolism

• Alzheimer’s Disease Pathways

• Parkinson’s Disease Pathways

• ALS Mechanisms

External Links

• UniProt: sptlc1-spt

• PubMed: sptlc1-spt